G B McDonald
G B McDonald
Over the last decade, there has been a dramatic decline in the frequency of organ failure, infection, and severe acute CVHD as causes of non-relapse mortality after allogeneic hematopoietic cell transplantation. Gastrointestinal CVHD, howev...
[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors] [0.03%]
蛋白酪氨酸激酶抑制剂治疗慢性移植物抗宿主病
C Martínez
C Martínez
Chronic graft versus host disease (GVHD) is still the main cause of long-term non-neoplastic morbidity and mortality in patients receiving an allogeneic hematopoietic stem cell transplantation. Treatment consists of a combination of cortico...
T Caballero Velázquez,J A Pérez Simón
T Caballero Velázquez
The NIH classification intends to standardize the diagnostic criteria for chronic CVHD and to establish prognosis groups that will help to identify patient risk and thus decide on the most appropriate treatment. This study assesses the pred...
R Fernández Alvarez
R Fernández Alvarez
Pegylation implies progress in filgrastim therapy. The addition of one molecule of polyethylene glycol (PEG) increases the drug's half-life by reducing renal excretion. A single dose of pegfilgrastim is equivalent to a daily administration ...
[Allogeneic transplantation in multiple myeloma patients: results and recommendations in February 2010] [0.03%]
异基因移植在多发性骨髓瘤患者中的疗效及2010年2月的建议
J A Pérez-Simón
J A Pérez-Simón
At this time, allogeneic transplantation should be offered only within the context of clinical trials. The likelihood of achieving prolonged complete remission with standard therapy with new drugs and autografting renders allogeneic transpl...
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation] [0.03%]
无关供者脐血联合输注干细胞移植
G Bautista,C Regidor,R Gonzalo-Daganzo et al.
G Bautista et al.
Our team conducted an original procedure of hematopoietic transplantation of umbilical cord blood (UCB) from an unrelated donor. The procedure consists of co-infusing hematopoietic stem cells selected from the blood of a third-party donor; ...
[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura] [0.03%]
瑞米普利姆：特发性血小板减少性紫癜治疗手段的新进展
M E Mingot Castellano
M E Mingot Castellano
Primary Immune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP) is an acquired immune disorder presenting with abnormal hemorrhagic symptoms resulting from a decrease in the number of platelets. The disorder used to be attribut...
[Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial] [0.03%]
骨髓干细胞移植治疗肌萎缩侧索硬化症的技术方面及临床试验初步结果
M Blanquer,M A Pérez Espejo,F Iniesta et al.
M Blanquer et al.
Patients with amyotrophic lateral sclerosis (ALS) experience progressive and irreversible paralysis as a result of the continued loss of motor neurons, which leads to death in less than five years. To date, there is no treatment that can ch...
[Clinical impact of HLA disparities in transplants from unrelated donors] [0.03%]
[无关供者的移植中HLA差异的临床影响]
D Gallardo
D Gallardo
The search for an unrelated donor must be based on the HLA typing of the donor and the host. PCR techniques have facilitated high-resolution HLA typing, but they have also elicited questions about the real impact of the various disparities ...